ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: PP10

Using a Mobile App to Facilitate Patient-Doctor Discussions to Make Informed Decisions Regarding ‘Painsomnia’

Shelley Fritz1, Kristine Carandang2 and Dawn Gibson3, 1ArthritisPower Patient Partner: CreakyJoints/Global Healthy Living Foundation, Tampa, FL, 2Chan Division of Occupational Science & Occupational Therapy, University of Southern California, Los Angeles, CA, 3Founder #SpoonieChat; CreakyJoints/Global Healthy Living Foundation Patient Partner, Upper Nyack, NY

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: autoimmune diseases, digital technologies and patient outcomes, PRO, Support and Education Groups

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: 3S041 ACR/ARHP: Patient Perspectives Poster Session

Session Type: Patient Perspectives Poster Session

Session Time: 12:00PM-2:00PM

Background/Diagnosis: As a patient with AS, Dawn founded #SpoonieChat to provide a space on twitter for people living with chronic diseases to support each other. One common theme in #SpoonieChat is the relationship between pain and sleep. ‘Painsomnia’ is a patient-generated term that addresses this cycle of pain and insomnia.

A follower of #SpoonieChat who experiences painsomnia is Shelley. Shelley was diagnosed with RA in 2012, following symptoms of symmetrical joint pain in hands and toes; fatigue, and malaise. After treatments including methotrexate, Plaquenil, and 5+ biologics, Shelley has made significant lifestyle changes and is currently on Rituximab. In addition to monthly bloodwork and physician exams, changes in Shelley’s treatment are based on her own data gathered by weekly symptom tracking.

To understand patients’ adaptations to manage painsomnia we used collective knowledge generated from #SpoonieChat with Shelley’s unique experiences as an individual patient recorded through patient reported outcomes measures via ArthritisPower.

Treatment: ArthritisPower is a patient-led, patient-generated, app-based research registry for arthritis, bone and inflammatory skin conditions and is free to use for patients like Shelley to track symptoms, to record subtle changes, to see how they are doing over a period of time whether on a new medication and/or in connection to sleep, physical function and other measures.  

 

By tracking pain interference, Shelley has found pain to be interrelated with levels of fatigue, sleep quality, and cognitive issues, thereby negatively impacting her quality of life. Figure 1 shows Shelley’s pain interference scores over a six-month period. Shelley identifies the causes of fluctuations by also tracking dates of flares, steroid usage, periods of illness, and restful vacations.

Maintenance:

Through this approach, Shelley worked with her rheumatologist to lessen the symptoms and progression of RA. Shelley continues to track these elements through ArthritisPower to look for patterns influenced by medication and maintenance strategies including diet, exercise, decreasing stress, and increasing sleep. This provides the doctor with information beyond blood work, lab tests and swollen joint counts to work with Shelley in managing her condition and treating the things that matter to her to help her live a better quality of life.

 

Quality of Life:

Doctor and patient conversations can be more meaningful when patient experienced data is systematically collected and discussed. Data gathered through ArthritisPower gives patients like Shelley, an organized way to talk with their doctor on each of the indicators of pain and sleep which affect cognitive function, physical function, depression.

 


Disclosure: S. Fritz, None; K. Carandang, None; D. Gibson, None.

To cite this abstract in AMA style:

Fritz S, Carandang K, Gibson D. Using a Mobile App to Facilitate Patient-Doctor Discussions to Make Informed Decisions Regarding ‘Painsomnia’ [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/using-a-mobile-app-to-facilitate-patient-doctor-discussions-to-make-informed-decisions-regarding-painsomnia/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/using-a-mobile-app-to-facilitate-patient-doctor-discussions-to-make-informed-decisions-regarding-painsomnia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology